Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia

Arthur E. Frankel, Michael W. Schuster, Joseph G. Jurcic

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Patients with chemotherapy-resistant acute myeloid leukaemia are rarely cured by non-allogeneic transplant therapies. Multiple new investigational agents have become available for treatment of these patients and there are few tools to permit rational drug and clinical trial selection. In this review, we describe the chemical and biological properties of some of these agents and some of their initial clinical activity to date. The selected agents react with either cell surface molecules or signal pathway intermediates and include antibody and antibody conjugates to CD33 and CD45. a fusion protein directed to the granulocyte-macrophage colony-stimulating factor receptor, an anti-sense oligonucleotide to Bcl2. a farnesyl transferase inhibitor, and a protein kinase C agonist/inhibitor. The challenge for the next decade will be how to select patients for particular molecularly targeted therapeutics and how to combine these agents.

Original languageEnglish (US)
Pages (from-to)55-71
Number of pages17
JournalBioDrugs
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2001

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this